tobaccouselungcancerHepatitisCq2yovariancancer65y.o.insufficientevidenceforscreeningraloxifenediabetes40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥6.5%≥ 200mg/dLGailmodelhypertensiontamoxifencervicalcancerq3y≥ 100mg/dL≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsaromataseinhibitorsFractureRiskAssessmentTooloverweight/ obesityaspirin60y.o.q15y≥ 140mg/dLanxietycolorectalcancerstatinTyrer-Cuzickmodel≥20%3%40-59 y.o.,ASCVD ≥10%, lowbleeding riskdepressionbreastcancerdyslipidemiadementia≥5.7%HIV75y.o.≤q2y≥ 126mg/dLwomenage 55-64 y.o.PREVENTequationcommunity-dwelling,postmenopausalwomenherpeszoster40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors1 dose; 2doses (2-6monthsapart) ifimmunocompcardiovasculardiseaseq1y2 doses,2-6monthsapart40-70 y.o.,ASCVD ≥10%, lowbleeding risk40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor40y.o.hormonetherapyq1ymammogramHepatitisB52y.o.Timedup andgo testmultidoseinitial series,then 1 doseat 2-6monthsq5ypneumococcalq1-2ymammogrambased on lifeexpectancy /health status50y.o.< 60y.o.tobaccouselungcancerHepatitisCq2yovariancancer65y.o.insufficientevidenceforscreeningraloxifenediabetes40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥6.5%≥ 200mg/dLGailmodelhypertensiontamoxifencervicalcancerq3y≥ 100mg/dL≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsaromataseinhibitorsFractureRiskAssessmentTooloverweight/ obesityaspirin60y.o.q15y≥ 140mg/dLanxietycolorectalcancerstatinTyrer-Cuzickmodel≥20%3%40-59 y.o.,ASCVD ≥10%, lowbleeding riskdepressionbreastcancerdyslipidemiadementia≥5.7%HIV75y.o.≤q2y≥ 126mg/dLwomenage 55-64 y.o.PREVENTequationcommunity-dwelling,postmenopausalwomenherpeszoster40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors1 dose; 2doses (2-6monthsapart) ifimmunocompcardiovasculardiseaseq1y2 doses,2-6monthsapart40-70 y.o.,ASCVD ≥10%, lowbleeding risk40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor40y.o.hormonetherapyq1ymammogramHepatitisB52y.o.Timedup andgo testmultidoseinitial series,then 1 doseat 2-6monthsq5ypneumococcalq1-2ymammogrambased on lifeexpectancy /health status50y.o.< 60y.o.

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. tobacco use
  2. lung cancer
  3. Hepatitis C
  4. q2y
  5. ovarian cancer
  6. 65 y.o.
  7. insufficient evidence for screening
  8. raloxifene
  9. diabetes
  10. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  11. ≥ 6.5%
  12. ≥ 200 mg/dL
  13. Gail model
  14. hypertension
  15. tamoxifen
  16. cervical cancer
  17. q3y
  18. ≥ 100 mg/dL
  19. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  20. aromatase inhibitors
  21. Fracture Risk Assessment Tool
  22. overweight / obesity
  23. aspirin
  24. 60 y.o.
  25. q15y
  26. ≥ 140 mg/dL
  27. anxiety
  28. colorectal cancer
  29. statin
  30. Tyrer-Cuzick model
  31. ≥20%
  32. 3%
  33. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  34. depression
  35. breast cancer
  36. dyslipidemia
  37. dementia
  38. ≥ 5.7%
  39. HIV
  40. 75 y.o.
  41. ≤ q2y
  42. ≥ 126 mg/dL
  43. women age 55-64 y.o.
  44. PREVENT equation
  45. community-dwelling, postmenopausal women
  46. herpes zoster
  47. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  48. 1 dose; 2 doses (2-6 months apart) if immunocomp
  49. cardiovascular disease
  50. q1y
  51. 2 doses, 2-6 months apart
  52. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  53. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  54. 40 y.o.
  55. hormone therapy
  56. q1y mammogram
  57. Hepatitis B
  58. 52 y.o.
  59. Timed up and go test
  60. multidose initial series, then 1 dose at 2-6 months
  61. q5y
  62. pneumococcal
  63. q1-2y mammogram based on life expectancy / health status
  64. 50 y.o.
  65. < 60 y.o.